000 05516cam a2200445Mi 4500
988 _aSpringer_Medicine_2017
999 _c96383
_d96383
_x1
001 96383
003 ES-MaUEC
005 20230102112751.0
006 m o d
007 cr |n|||||||||
008 170803s2017 sz o 000 0 eng d
020 _a3319572253
_q(electronic bk.)
020 _a9783319572253
_q(electronic bk.)
020 _z3319572245
020 _z9783319572246
040 _aYDX
_cYDX
_dN$T
_dEBLCP
_dNJR
_dGW5XE
_dKOS
_dN$T
_dOCLCO
_dUAB
_dYDX
_dOCLCO
_dESU
_dAZU
_dUPM
_dIOG
_dCOO
_dOH1
_dOCLCQ
_dMERER
_dVT2
_dOCLCQ
_dAUD
_dOCLCQ
_dOCLCO
_dOCLCQ
_dOCLCO
_dOCLCQ
_dMERUC
_dES-MaUEC
_bspa
050 4 _aRC644
_b2017 EB
245 0 0 _aPET/CT in Hodgkin's lymphoma
_cIrfan Kayani, editor.
264 1 _aCham, Switzerland
_bSpringer
_c2017.
300 _a1 recurso en línea
336 _aTexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _atext file
_bPDF
490 0 _aClinicians' guides to radionuclide hybrid imaging, PET/CT
500 _aSpringerLink
505 0 _aForeword; Preface; Acknowledgements; Contents; Contributors; 1: Hodgkin Lymphoma; 1.1 Epidemiology; 1.2 Clinical Presentation; 1.3 Diagnosis; 1.4 Pathology and Classification; 1.5 Staging; 1.6 Prognostic Factors at Baseline; 1.7 Nodular Lymphocyte Predominant Hodgkin Lymphoma; Further Reading; 2: Pathology of Hodgkin Lymphoma; 2.1 NLPHL: Clinical, Biological, Morphological and Immunophenotipical Features; 2.2 cHL: Clinical, Biological, Morphological and Immunophenotipical Features; 2.3 cHL Variants; 2.3.1 Nodular Sclerosis; 2.3.2 Mixed Cellularity; 2.3.3 Lymphocyte Rich.
505 8 _a2.3.4 Lymphocyte DepletedFurther Reading; References; 3: Management of Hodgkin Lymphoma; 3.1 Baseline Evaluation; 3.2 Historical overview of HL treatment; 3.3 Upfront Treatment Modalities; 3.4 Early Stage Favourable cHL; 3.5 Early Stage Unfavourable cHL; 3.6 Treatment of Advanced-Stage Disease; 3.7 Follow-Up Evaluation; 3.8 Management of Refractory and Relapsed Disease; 3.9 Novel Agents; 3.10 Management of NLPHL; Further Reading; 4: Radiological Imaging in Lymphoma; 4.1 Introduction; 4.2 Primary Diagnosis/Staging; 4.3 Response Assessment; 4.4 The Future; References.
505 8 _a5: 18F-FDG PET/CT in Hodgkin's Lymphoma5.1 Pretreatment Assessment; 5.1.1 Staging; 5.1.2 Prognostication; 5.2 Interim Scanning; 5.2.1 Prognostication; 5.3 Response-Adapted Therapy; 5.4 End of Treatment Scanning; 5.5 PET Before High-Dose Chemotherapy or Transplant; 5.6 Surveillance; 5.7 Radiotherapy Planning; 5.8 Combined Scanning of PET/CT with Contrast-Enhanced Diagnostic Quality CT; 5.9 Scan Interpretation; References; 6: 18F-FDG PET/CT: Normal Variants, Artefacts and Pitfalls in Lymphoma; 6.1 Introduction; 6.2 General PET/CT Issues; 6.2.1 False Positive.
505 8 _a6.2.2 False Negative6.3 Anatomy Based; 6.3.1 Lymphatic Sites; 6.3.1.1 Waldeyer's ring; 6.3.1.2 Lymph Nodes; 6.3.1.3 Thymus; 6.3.1.4 Spleen; 6.3.2 Extralymphatic Sites; 6.3.2.1 CNS; 6.3.2.2 Thyroid; 6.3.2.3 Lungs; 6.3.2.4 Liver; 6.3.2.5 GI; 6.3.2.6 Renal Lymphoma; 6.3.2.7 Bone Marrow; 6.3.2.8 Skin; Further Reading; 7: PET/CT in Hodgkin's Lymphoma: Teaching Cases; 7.1 Case 1: Upstaging of Disease with PET/CT; 7.1.1 Teaching Points; 7.2 Case 2: Early Stage Unfavourable Disease; 7.2.1 Teaching Points; 7.3 Case 3: Splenic Involvement on PET/CT; 7.3.1 Teaching Points.
505 8 _a7.4 Case 4: Reactive Marrow Activity Pre-Treatment7.4.1 Teaching Points; 7.5 Case 5: Bone Marrow Involvement; 7.5.1 Teaching Points; 7.6 Case 6: Brown Fat Activity; 7.6.1 Teaching Points; 7.7 Case 7: Thymic Hyperplasia; 7.7.1 Teaching Points; 7.8 Case 8: Reactive Bone Marrow and Spleen Activation; 7.8.1 Teaching Points; 7.9 Case 9: Metabolic Remission; 7.9.1 Teaching Points; 7.10 Case 10: Interim PET Scan with Uptake Score of 3; 7.10.1 Teaching Points; 7.11 Case 11: Interim PET Scan with Uptake Score of 4; 7.11.1 Teaching Points.
520 3 _aThis book is a pocket guide to the practice of PET/CT imaging of Hodgkin's lymphoma. The role of PET/CT in Hodgkin's lymphoma, the characteristic findings and patterns, and the advantages and limitations of this hybrid modality are all clearly described. In addition, information is provided on clinical presentation, diagnosis, staging, pathology, management, and conventional radiological imaging. A useful pictorial atlas is included at the end of the book. PET/CT in Hodgkin's Lymphoma is published within the Springer series Clinicians' Guides to Radionuclide Hybrid Imaging, which is aimed at referring clinicians, nuclear medicine/radiology physicians, radiographers/technologists, and nurses who routinely work in nuclear medicine and participate in multidisciplinary meetings. Compiled under the auspices of the British Nuclear Medicine Society, the series is the joint work of many colleagues and professionals worldwide who share a common vision and purpose in promoting and supporting nuclear medicine as an important imaging specialty for the diagnosis and management of oncological and non-oncological conditions.
650 7 _2embne
_9676009
_aHodgkin, Enfermedad de
650 7 _2embne
_9140122
_aHematología
700 1 _aKayani, Irfan.
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-57225-3
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b02/2018
_dz
_e-
_zSI